



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/620,725	
	Filing Date	July 15, 2003	
	First Named Inventor	Gregory M. LANZA	
	Art Unit	1615	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	6	Attorney Docket Number	532512000401

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 (2 pages) Return postcard
<div>Remarks</div> <p>Customer No. 25225</p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Karen R. Zachow, Ph.D. - 46,332
Signature	<i>Karen R. Zachow</i>
Date	February <u>25</u> , 2004


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: <u>2.25.2004</u>	Signature: <i>Rhea Amid</i> (Rhea Amid)



PATENT
Docket No. 532512000401

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on February 25, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gregory M. LANZA et al.

Serial No.: 10/620,725

Filing Date: July 15, 2003

For: LIGAND-TARGETED EMULSIONS
CARRYING BIOACTIVE AGENTS

Examiner: Not Yet Assigned

Group Art Unit: 1615

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/697,796 filed 27 October 2000, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532512000401. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 25, 2004

Respectfully submitted,

By: Karen R. Zachow
Karen R. Zachow, Ph.D.
Reg. No. 46,332
Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5191
Facsimile: (858) 720-5125



Form PTO-1679

Docket Number 532512000401

Application Number 10/620,725

Applicant

Gregory M. LANZA et al.

Filing Date July 15, 2003

Group Art Unit 1615

Mailing Date February 25, 2004INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	05/1990	4,927,623	Long, Jr.	424	5	
	2.	01/1991	4,987,154	Long, Jr.	514	772	
	3.	12/1991	5,077,036	Long, Jr.	424	5	
	4.	05/1992	5,114,703	Wolf et al.	424	5	
	5.	12/1992	5,171,755	Kaufman et al.	514	749	
	6.	04/1994	5,304,325	Kaufman et al.	252	312	
	7.	05/1994	5,310,505	Hedden et al.	252	301.4	
	8.	09/1994	5,350,571	Kaufman et al.	424	9	
	9.	02/1995	5,393,524	Quay	424	9	
	10.	03/1995	5,401,634	Milbrath	435	6	
	11.	04/1995	5,403,575	Kaufman et al.	424	1.89	
	12.	08/1996	5,542,935	Unger et al.	604	190	
	13.	11/1997	5,690,907	Lanza et al.	424	9.5	
	14.	07/1998	5,780,010	Lanza et al.	424	9.32	
	15.	07/1998	5,785,950	Kaufman et al.	424	1.89	
	16.	09/1999	5,985,371	Lanza et al.	424	1.21	
	17.	11/1999	5,989,520	Lanza et al.	424	9.32	
	18.	09/2000	6,120,794	Liu	424	450	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	19.	02/1995	WO 95/03829	PCT			x	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Application Number 10/620.725

Applicant

Gregory M. LANZA et al.

(Use several sheets if necessary)

Filing Date July 15, 2003

Group Art Unit 1615

Mailing Date February 25, 2004

Examiners' Initials	Ref. No.
---------------------	----------

Ref.
No.

Title

Collins-Gold et al., *Advanced Drug Delivery Reviews*, 5(3):189-208 (1990)

Leveille-Webster et al., Hepatology, 23(6):1631-1641 (1996)

Leveille-Webster et al., J. Magn. Reson. Imaging, 4:325-330 (1994)

Reimer et al., Radiology, 193(1):527-531 (1994)

Reimer et al., J. Magn. Reson. Imaging, 8(3):687-689 (1998)

Reimer et al., J. Magn. Reson. Imaging, 2(2):177-181 (1992)

Reimer et al., Radiology, 182(2):565-569 (1992)

Sche et al., Chem. & Bio., 6(10):707-716 (1999)

Stadler, Dev. Biol. Stand. Basel, Karger, 101:45-48 (1999)

Tarr et al., Pharm. Res., 4(2):162-165 (1987)

Wittrup, Trends Biotechnol., 17:423-424 (1999)

Wright et al., "Acad. Radiol., Supp.1:S240-242 (1998)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.